Telbivudine Prevents Vertical Transmission From HBeAg-Positive Women With Chronic Hepatitis B

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 5, 2012, Pages 520-526

  Pan, Calvin Q ^a   Han, Guo Rong ^b   Jiang, Hong Xiu ^b   Zhao, Wei ^b   Cao, Min Kai ^c   Wang, Cui Min ^b   Yue, Xin ^b   Wang, Gen Ju ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Nanjing Second Hospital   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

HBsAg; LdT; Mother to Child Transmission; Newborn

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADULT; ANTIBODY TITER; APGAR SCORE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; PNEUMONIA; POSTPARTUM HEMORRHAGE; PREGNANT WOMAN; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SEROCONVERSION; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; VIREMIA;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; NUCLEOSIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; PYRIMIDINONES;

EID: 84862776962     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.01.019     Document Type: Article

References (22)

1. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
2. Jonas M.M. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009, 29(Suppl 1):133-139.
3. ter Borg M.J., Leemans W.F., de Man R.A., et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008, 15:37-41.
4. Tong M.J., Pan C.Q., Hann H.W., et al. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011, 56:3143-3162.
5. Hung J.H., Chu C.J., Sung P.L., et al. Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy. J Chin Med Assoc 2008, 71:155-158.
6. Pan C.Q., Duan Z.P., Bhamidimarri K.R., et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012, 12:452-459.
7. Pan C.Q., Zhang J.X. Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci 2005, 2:36-40.
8. Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16:94-103.
9. Wiseman E., Fraser M.A., Holden S., et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009, 190:489-492.
10. van Zonneveld M., van Nunen A.B., Niesters H.G., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10:294-297.
11. van Nunen A.B., de Man R.A., Heijtink R.A., et al. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000, 32:1040-1041.
12. Zou H., Chen Y., Duan Z., et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012, 19:e18-e25.
13. Interim report 1 January 1989 through 30 June 2011 The Antiretroviral Pregnancy Registry, Accessed October 10, 2011. http://www.apregistry.com/forms/interim_report.pdf.
14. Euler G.L., Wooten K.G., Baughman A.L., et al. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics 2003, 111:1192-1197.
15. Liang X., Bi S., Yang W., et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
16. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
17. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
18. Xu D.Z., Yan Y.P., Choi B.C., et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002, 67:20-26.
19. Dienstag J., Easley C., Kirkpatrick P. Telbivudine. Nat Rev Drug Discov 2007, 6:267-268.
20. Ruiz-Sancho A., Sheldon J., Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 2007, 7:751-761.
21. Han G.R., Cao M.K., Zhao W., et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011, 55:1215-1221.
22. Liaw Y.F., Gane E., Leung N., et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.